Company Insights

NNOX customer relationships

Explore interactive graphBrowse insights index
NNOX customer relationship map

Nano‑X Imaging (NNOX): channel-first commercialization with partner leverage

Nano‑X Imaging builds and sells the Nanox.ARC digital X‑ray system and associated imaging and AI services through a network of exclusive distributors, hospital pilot partners and AI/IT integrators. The company monetizes primarily by licensing and distributing its imaging hardware and by commercializing its Nanox.AI solutions via strategic channel partners, with geographic exclusivity and service responsibilities shifted to local distributors. For investors, Nano‑X is a channel‑dependent, early commercial business that scales by signing regional distribution and integration agreements rather than building a direct sales force.

Explore deeper coverage and relationship mapping at https://nullexposure.com/.

How Nano‑X goes to market and why relationships matter

Nano‑X’s operating model is channel‑led and partner‑centric. The company signs exclusive distribution agreements (often country‑ or region‑wide) that place marketing, installation and local support in the hands of third parties. At the same time, Nano‑X pairs hardware deals with AI and integration partners to deliver end‑to‑end imaging solutions.

Key business model characteristics:

  • Contracting posture: Partner‑first; Nano‑X relies on exclusivity agreements to open markets and transfer operational duties to distributors.
  • Concentration: Commercial progress relies on a growing but still modest set of channel partners across discrete regions — rollout success depends on each agreement converting pilot sites into recurring service revenue.
  • Criticality: Distributors and integrators are critical for deployment, regulatory interfacing and local customer support; execution risk is therefore operationally concentrated outside of Nano‑X’s direct control.
  • Maturity: Financials show early commercialization: TTM revenue of $12.3M with a negative gross profit of $12.06M and negative operating margins, indicating the company is still scaling product‑market fit and channel throughput (latest quarter through 2025Q3).

For a gateway to relationship intelligence and transaction timelines visit https://nullexposure.com/.

Customer and channel relationships — what the company has announced

Below are the partner relationships disclosed in Nano‑X’s recent materials and press coverage. Each entry summarizes the commercial role and cites the public source.

X‑ray (Czech distributor)

Nano‑X announced a distribution agreement with X‑ray to introduce the Nanox.ARC system to healthcare providers across the Czech Republic, positioning X‑ray as the local channel for sales, installation and support. This was disclosed on the company’s 2025 Q3 earnings call.

3DR Labs, LLC

3DR Labs will offer Nano‑X’s Nanox.AI FDA‑cleared solutions across its network of more than 1,800 hospitals and imaging centers, acting as a major North American go‑to‑market partner for AI‑enabled imaging services; the collaboration was announced in a GlobeNewswire release in November 2025 and referenced in the 2025 Q3 earnings call.

Cedars‑Sinai

Nano‑X cited Cedars‑Sinai as one of the prominent organizations in its expanding collaboration network, indicating ongoing pilot and clinical engagement with a large U.S. health system as part of commercialization and validation activities; this was noted on the 2025 Q3 earnings call.

Covera Health

Nano‑X expanded its existing agreement with Covera Health to extend AI and quality‑assurance capabilities tied to imaging workflows, using Covera’s analytics to support clinical validation and image interpretation; the expansion was referenced on the 2025 Q3 earnings call.

Alphea France SARL (part of Altair Group)

Nano‑X signed a distribution agreement in France with Alphea France SARL, part of the Altair Group, which will manage marketing and local support for Nanox.ARC installations in France; this agreement was announced on the 2025 Q3 earnings call.

Intec SRL (Argentina)

Intec SRL was named Nano‑X’s exclusive distributor for the Nanox.ARC system in Argentina and will oversee marketing, distribution, installation and support in that market, as described in GlobeNewswire (Feb 19, 2026) and in earlier Nano‑X releases (April 17, 2025) tied to the company’s FDA clearance and Latin America strategy.

Vaso Corporation (VASO)

Nano‑X described a commercial synergy with Vaso Corporation and VHC IT to connect Nano‑X’s FDA‑cleared imaging AI with VHC IT’s systems‑integration and customer operation capabilities, positioning Vaso as an integration and IT services partner; this was detailed on the 2025 Q3 earnings call.

Imperial Imaging Technology LLC

Imperial Imaging Technology will serve as Nano‑X’s distributor across multiple southeastern U.S. states (Georgia, Alabama, Tennessee, North Carolina, South Carolina and Northern Florida), handling sales, installation and service for Nanox.ARC units; the agreement was announced in GlobeNewswire on March 3, 2026 and reported in related press coverage.

Adriamed d.o.o. Beograd (Adriamed)

Adriamed became Nano‑X’s exclusive partner for the Nanox.ARC system in Serbia, Montenegro and Bosnia and Herzegovina, responsible for marketing, distribution, installation and support in the region, as publicized via GlobeNewswire on January 14, 2026.

Hospital Privé Jacques Cartier MASSY

Hospital Privé Jacques Cartier MASSY is participating in deployments (via local partner Olympe Imagerie) to demonstrate Nanox.ARC’s potential in lung cancer screening programs in Paris hospitals, positioning Nano‑X for clinical validation on a high‑value screening pathway; this collaboration was reported in coverage of pilot activity in FY2025.

Olympe Imagerie

Olympe Imagerie partnered with Nano‑X on November 14 (reported FY2025) to operate and demonstrate Nanox.ARC systems in Paris‑area facilities, supporting pilot programs focused on lung cancer screening and early detection initiatives.

Why these relationships change the investment equation

The collection of exclusivity deals, integrator partnerships and hospital pilots shows a deliberate commercial strategy to scale via local operators rather than direct sales. That reduces Nano‑X’s fixed sales overhead but transfers deployment and regulatory execution risk to partners. With TTM revenue of $12.3M, negative gross profit and operating losses, the company’s valuation and future upside depend on converting these channel agreements into repeatable, serviceable revenue streams and on successful installations in major health systems.

Risks and what to watch

  • Partner execution risk: Distributor performance, installation throughput and local regulatory navigation will determine revenue conversion rates.
  • Early commercial metrics: Low absolute revenue and negative gross profit highlight the need to demonstrate profitable unit economics at scale.
  • Concentration of rollout: Many agreements are exclusive for discrete geographies; failure of one regional partner to ramp could materially slow adoption in that market.
  • Clinical validation path: Partnerships with major hospitals (e.g., Cedars‑Sinai) and screening pilots in Paris are critical proof points to drive payer and large‑system adoption.

For a tactical summary of partner timelines and visibility into installations, visit https://nullexposure.com/.

Concluding takeaway: Nano‑X is executing a channel‑first commercial playbook that amplifies its hardware and AI value propositions but creates outsized dependence on distributor and integrator execution; investors should focus on partner conversion metrics, installation cadence, and margins as the next inflection points.

Learn more about relationship analysis and situational intelligence at https://nullexposure.com/.